EMT Targeting Vaccination, Concurrent with Chemoimmunotherapy, in Advanced NSCLC
Abstract
Immunotherapy with immune checkpoint inhibitors (ICI) is a significant treatment advance for non-small cell lung cancer (NSCLC) and the only therapy that can lead to long term survival, although this occurs in less than 20% of patients. Despite this improvement, the majority of patients die within 2 years of diagnosis. Our challenge is to make immunotherapy work for all patients with lung cancer. Once T-cells are appropriately activated, the cells will home to any site of disease, migrate from the blood stream into the tissue, and kill the cancer cells until none remain. Furthermore, if memory is generated tumor specific T-cells will remain in a resting state able to re-expand if the cancer returns. ICI therapy is most effective in patients who have started their own immune response before treatment. Studies have found that patients with higher levels of CD8+ T cells in their tumors (TIL) prior to treatment respond the best to ICI. Unfortunately, most patients with NSCLC have minimum levels of TIL. Our objective, in this randomized Phase II clinical trial is to evaluate whether a multiple antigen vaccine, STEMVAC, given with GM-CSF as an adjuvant, and used to immunize NSCLC patients who are not responding to immuno-chemotherapy, increases the level of CD8 T-cells in the tumor. STEMVAC might jump start the immune system and lead to more clinical responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1191137
Entities
People
- Laura Riolobos
Organizations
- University of Washington